Intelligent Medicine Acquisition Corp.

The Beginning of the end of disease

About Us

We are a newly organized blank check company incorporated in Delaware, formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. While we may pursue an initial business combination with a company in any sector, we intend to focus our search on life science companies that are using artificial intelligence (“AI”), machine learning (“ML”) and big data to create and power a new model of drug discovery through research and development that is far faster, less expensive and more predictable than the decades-old system of drug development we still follow today.

With a broadening set of applications for biotechnology that includes research tools and infrastructure, diagnostics, therapeutics, data, and industrial outputs, we believe the life sciences sector offers compelling opportunities for investors who possess a broad overview and understand the trends and themes. We combine a unique team of thought leaders who have deep experience and national reputations within academia, government and industry that will enable us to attract and evaluate the over 250 companies utilizing these new tools across the life sciences industry.

Press Releases

SEC Filings

All Filings for Intelligent Medicine Acquisition Corp. Available via EDGAR

View Filings

Our Team

Jack D. Hidary, Director, Board Chair

Jack D. Hidary is a successful serial entrepreneur.

After his studies at Columbia University, Jack accepted a research fellowship at the National Institutes of Health (NIH). At NIH, Jack focused on fMRI, PET and other medical imaging modalities. He was one of the first researchers to apply neural network AI approaches to medical imaging.

Jack then established EarthWeb/Dice, a company dedicated to the needs of tech professionals. Jack led the company from its inception through three rounds of investment and then its IPO. As Chairman and CEO of the public company, Jack continued to grow the company and engage with shareholders, customers and analysts. (NYSE: DHX) www.dice.com

Jack established the Hidary Foundation to focus on oncology research with particular focus on immunotherapies and on genomic drivers.

Greg Simon, Director, CEO/CFO

Most recently, Greg was the Executive Director of the White House Cancer Moonshot Task Force, a position created by President Barack Obama and for which he was chosen by Vice President Joe Biden in March 2016. In 2017 Simon co-founded and served as President of the Biden Cancer Initiative.

Previously In his career, Greg held senior positions in both chambers of Congress, was Chief Domestic Policy Advisor to Vice President Al Gore, and was a senior strategy consultant to a variety of international technology CEO’s.

With Michael Milken, Simon co-founded and led FasterCures and the Melanoma Research Alliance. He was the Senior Vice President at Pfizer for worldwide policy and public engagement and was the CEO of Poliwogg, a financial services company creating unique capital market opportunities in healthcare and life sciences. He has developed a reputation as a visionary strategist, a dynamic public speaker and writer, and as a knowledgeable analyst of emerging trends in healthcare, information technology, innovative drug research and development and patient advocacy.

Patience Marime-Ball, Director

Patience Marime-Ball is a seasoned banker, investor and philanthropist, in 2018, Ms. Marime-Ball founded Women of the World Endowment to harness the power of the capital markets to drive lasting change for women and girls. She is an inaugural member of Apollo Global Management, Inc.’s Impact Advisory Committee; serves on the Investment Committee of Align Impact; is an investor in Purple Arch Ventures; and is an early- stage investor with Golden Seeds LLC.

Dr. Kavita Patel, Director

Kavita Patel, M.D. served in the Obama Administration as director of policy for the Office of Intergovernmental Affairs and Public Engagement in the White House, where she played a key role in policy development and evaluation of policy initiatives connected to health reform, financial regulatory refor and economic recovery issues. Dr. Patel currently serves on the board of directors of SelectQuote, Inc. (NYSE: SLQT) and Sigilon Therapeutics, Inc. (Nasdaq SGTX). Dr. Patel is also a Venture Partner at New Enterprise Associates and a Young Global Leader at the World Economic Forum.

Joseph Shocken, Director

Joseph Schocken is the Co-founder and Chairman of Broadmark Realty Capital (NYSE: BRMK) and President of Tranceka Capital, LLC (formerly Broadmar Capital, LLC). He has more than 40 years of experience in investment banking, extensive knowledge of the financial services industry and established relationships with both strategic and institutional investors throughout the United States and internationally.

Geoff Ling, Advisor

Geoffrey S. Ling, M.D., Ph.D., is the CEO of On Demand Pharmaceuticals. He served as the Founding Director of the Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office from 2014 until 2016.

His programs include Revolutionizing Protheses (brain controlled prosthetic arm), and battlefield medicine, (point of care drug manufacturing). The current Covid-19 vaccines are from his DARPA genomic vaccine program.

Prominent in his DARPA research portfolio are Preventing Violent Explosive Neuro Trauma (PREVENT), prevention of explosive blast traumatic brain injury,[3] Revolutionizing Prostheses (RP), development of responsive, braincontrolled, artificial arms, Predicting Health and Disease (PHD), combination of biomarkers and advanced analytics to diagnosis of disease in the presymptomatic state and Battlefield Medicine, development of point-of-care drug manufacturing technology.

Samir N. Khleif, Advisor

Dr. Khleif is an internationally recognized pioneer oncologist, cancer researcher, inventor and a Key Opinion Leader in immunotherapy, and clinical and regulatory immunotherapy of cancer.

He is a Biomedical Scholar and Professor and Director of the Immunology and Immunotherapy Center at Oncology at Georgetown University and the founder and CEO of Georgiamune. He previously served as the founding Director of the Georgia Cancer Center at Medical College of Georgia; the founding CEO of the King Hussein Cancer Center and Hospital; Chief of Cancer Vaccine Section at NCI/NIH and Special Assistant to the Commissioner of FDA leading the FDA’s Transformational Critical Path Initiative for Oncology.

Dr. Khleif as one of the early pioneers in immunotherapeutic drug development. He is a member of many national and international committees including the National Cancer Policy Forum and serves on the board or the scientific advisory board of many biotechnology companies. He also served on the Advisory Boards of The Biden Cancer Initiative. The author of many peer reviewed scientific research articles and the holder of more than 100 issued or pending patents.

Usama Fayyad, Advisor

Usama Fayyad, Ph.D is a data scientist considered as one of the founders of the field of Data Mining. and is a named inventor on over 30 patents.

Mr. Fayyad also is a Co-founder of KDD conferences, the ACM SIGKDD association for Knowledge Discovery and Data Mining. He is Chairman at Open Insights which he founded in 2008 focusing on AI/ML/BigData, Data strategy, and new business models for Data. He is the Inaugural Executive Director of the Institute for Experiential AI at Northeastern University where he is also professor of computer science. He was co-cofounder and CTO of OODA Health, Inc. (2017-2019), a San Francisco VC-funded company aiming to streamline healthcare claims and payments processing in the U.S. He served as Global Chief Data Officer at Barclays Bank in London (2013-2016) and in addition to his Group Managing Director role, he was CIO of Risk, Finance, & Treasury Technology. He was Chairman/CEO/CTO at several Seattle/Silicon Valley tech startups and the first person to hold the title: Chief Data Officer when Yahoo! acquired his 2nd startup in 2004.

Jonathan J. Fleming, Advisor

Jonathan J. Fleming is the Managing Partner of Pimlico Pond Investments, a venture capital investment firm based in Newton MA. He is the cofounder and Chairman of two VC backed ALS companies, QurAlis and Enclear Therapies, as well as the Chairman of Onc.ai a VC backed AI/ML company focused on clinical decision support tools for oncologists. From 1996 to 2015, Mr. Fleming was the Managing General Partner of Oxford Bioscience Partners. He has built companies with six Nobel Laureates.

William A. Haseltine, Advisor

William A. Haseltine is well known for his pioneering work on cancer, HIV/AIDS, and genomics. Dr. Haseltine is a pioneer in biotechnology having founded more than a dozen biotechnology companies in fields ranging from development of cutting-edge pharmaceuticals to new materials and fuels. He founded Human Genome Sciences, Inc. and was the Chairman and CEO of the company for twelve years.

Llew Keltner, Advisor

Llew Keltner, MD, PhD, has a 40-year career in biopharma drug and business development. He is Chief Executive Officer of EPISTAT, an international healthcare technology transfer, corporate risk management and healthcare strategy company that he founded in 1972. Dr. Keltner was the Chief Executive Officer of AgonOx, a biotech company developing OX40 agonists for use in cancer therapy, from 2011 to 2013. He was the President of Novici Biotech, a privately-held gene and protein optimization firm in 2010 and 2011. He is on numerous boards of biotechnology companies.

Peter Knight, Advisor

Peter S. Knight is a Managing Partner at Cyan Capital Partners, a fund building capacity in the field of sustainable finance. Prior to Cyan, Peter was a Founding Partner at Generation Investment Management where he helped build, with his partners Al Gore and David Blood, a leading global sustainable investing firm with assets under management now exceeding $28 billion. Previously, Mr. Knight was a Managing Director of Met West Financial, an LA based asset management company.

Sue Siegel, Advisor

Sue Siegel holds positions on the board of Illumina, Align, Nevro, the Kaiser Family Foundation, and UC Berkeley Bakar BioEnginuity Hub. Previously, Ms. Siegel was GE’s Chief Innovation officer, CEO of GE Ventures & Licensing, and CEO of Healthymagination. Prior to GE, Ms. Siegel was a VC General Partner at Mohr Davidow Ventures. During the early days of the Human Genome Project, Ms. Siegel led Affymetrix, one of the fastest growing genomics companies. She drove its growth from pre-venue start up to a multi-billion publicly-listed company.